Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PD of CBT-009 in Healthy Volunteers
NCT05372991Phase 2Completed
- Sponsor
- Cloudbreak Pharma
- Start
- Jul 2022
- Primary completion
- Jan 2023
- Modality
- Classical Binding Small Molecules, Prodrugs/Conditional Activator Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of CBT-009 in myopia, sponsored by Cloudbreak Pharma. Started Jul 2022; status: completed.
02
Drugs
CBT-009
03
Conditions
myopia
Beyond the preview
Go deeper on NCT05372991.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05372991.